latest news releases from the newsroom
Jerini AG Presents Clinical Development Update for Icatibant in the Treatment of Hereditary Angioedema
BERLIN, March 6, 2006 (PRIMEZONE) -- Jerini AG (FSE:J14) announced today that clinical trial progress from its ongoing Phase III clinical trial for hereditary angioedema (HAE) was presented by Dr. Alvin Davis, Harvard Medical School, at the American Academy of Allergy Asthma and Immunology Conference (AAAAI) on March 4, 2006 in Miami, Florida. Dr. Davis reported that 153 subcutaneous open-label treatments with Icatibant have been administered for abdominal, cutaneous, and laryngeal HAE attacks, with 91 percent of patients being treated with only a single injection within 24 hours. Eight percent of patients received a second injection and one percent received three injections within 24 hours. In the ongoing Phase III trials, patients completing the randomised study phase are eligible to receive Icatibant in the open-label study phase (for ethical reasons, laryngeal attacks, which are potentially life-threatening are only treated in the open-label phase). In addition, 48 percent of participating Phase III patients have been treated with Icatibant in multiple HAE attacks, with one patient receiving more than 30 treatments.
ATA Airlines, Inc.
ATA Reports February Scheduled Service Traffic
INDIANAPOLIS, March 5, 2006 (PRIMEZONE) -- ATA Airlines, Inc., today reported that February scheduled service traffic decreased 49.4 percent from 2005 to 266.0 million RPMs (revenue passenger miles). Capacity decreased 58.3 percent compared to 2005 to 375.2 million ASMs (available seat miles). ATA's February scheduled service passenger load factor increased 12.5 points to 70.9 percent. There were 182,642 passengers enplaned in February, a decrease of 57.6 percent.
Murray, Frank & Sailer LLP
Investor Notice: A Shareholder Class Action Has Been Filed Against Take-Two Interactive Software, Inc. -- TTWO
NEW YORK, March 3, 2006 (PRIMEZONE) -- Murray, Frank & Sailer LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, on behalf of shareholders who purchased or otherwise acquired the securities of Take-Two Interactive Software, Inc. ("Take-Two" or the "Company") (Nasdaq:TTWO) between October 25, 2004 and January 27, 2006, inclusive (the "Class Period"). Murray, Frank & Sailer LLP is seeking to pursue remedies under the Securities Exchange Act of 1934 against defendants Take-Two, Paul Eibeler, Karl H. Winters, and Gary Lewis (the "defendants").
IElement Corporation Announces Fourth Quarter Sales
DALLAS, March 3, 2006 (PRIMEZONE) -- IElement Corporation (OTCBB:IELM) (Frankfurt:SZQ1) (Frankfurt:IELM), a nationwide provider of advanced communications services and Voice over Internet Protocol (VoIP) solutions, announced today that fourth quarter customer renewals and new sales beat expectations for the second straight quarter and totaled $600,513.12. The company will earn this contracted revenue over the next 12-36 months based on the duration of the new agreement each customer signed with IElement.
Aquila Subsidiary Reaches Agreement to Sell Everest
KANSAS CITY, Mo., March 3, 2006 (PRIMEZONE) -- As part of its continuing plan to divest non-strategic assets, Aquila, Inc. (NYSE:ILA) today announced that its subsidiary, Everest Global Technologies Group, LLC ("EGTG"), has signed an agreement to sell its cable, broadband Internet, and telephony business serving customers in the greater Kansas City metropolitan area. An acquisition subsidiary of Seaport Capital Partners III, L.P., a private equity investment partnership, has agreed to purchase the Lenexa, Kansas-based business. Aquila owns over 97 percent of the membership interests of EGTG.
Beacon's Fixed Annuity Premium Study Reports Fourth Quarter's Best-Selling Products
EVANSTON, Ill., March 3, 2006 (PRIMEZONE) -- MasterDex, an indexed annuity issued by Allianz Life Insurance Company of North America(1), was the quarter's top-selling product in the Beacon Research Fixed Annuity Premium Study for the sixth consecutive period. Four book value products -- New York Life's LifeStages/MainStay Single Premium Fixed Annuity(2), Allstate Financial's (NYSE:ALL) Preferred Performance, John Hancock's (NYSE:MFC) GPA Plus, and Genworth Financial's (NYSE:GNW) SecureLiving(sm) Advantage -- were numbers two, three, four and five, respectively. Fourth quarter results include sales of some 188 products and 49 insurance companies.